Citations (36)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Carol H. Wysham, Jay Lin & Louis Kuritzky. (2017) Safety and efficacy of a glucagon-like peptide-1 receptor agonist added to basal insulin therapy versus basal insulin with or without a rapid-acting insulin in patients with type 2 diabetes: results of a meta-analysis. Postgraduate Medicine 129:4, pages 436-445.
Read now
Read now
Lisa Arnetz, Neda Rajamand Ekberg & Michael Alvarsson. (2014) Sex differences in type 2 diabetes: focus on disease course and outcomes. Diabetes, Metabolic Syndrome and Obesity 7, pages 409-420.
Read now
Read now
John Gerich. (2013) Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies. International Journal of General Medicine 6, pages 877-895.
Read now
Read now
Roberto Anichini, Sabrina Cosimi, Alberto Di Carlo, Paola Orsini, Alessandra De Bellis, Giuseppe Seghieri, Flavia Franconi & Fabio Baccetti. (2013) Gender difference in response predictors after 1-year exenatide therapy twice daily in type 2 diabetic patients: a real world experience. Diabetes, Metabolic Syndrome and Obesity 6, pages 123-129.
Read now
Read now
Articles from other publishers (32)
Sun Ah Choi, Hye Jin Jee, Katrina Joy Bormate, Yeonjae Kim & Yi-Sook Jung. (2023) Sex Differences in the Preventive Effect of Cardiovascular and Metabolic Therapeutics on Dementia. Biomolecules & Therapeutics 31:6, pages 583-598.
Crossref
Crossref
Jun Yao, Minlu Zhang, Xia Zhang & Junqing Zhang. (2023) Impact of Type 2 Diabetes Duration on the Efficacy and Safety of Add-on Lixisenatide in Asian Individuals Receiving Basal Insulin: A Pooled Analysis. Diabetes Therapy 14:4, pages 653-669.
Crossref
Crossref
Timothy M. E. Davis, Anna Giczewska, Yuliya Lokhnygina, Robert J. Mentz, Naveed Sattar & Rury R. Holman. (2022) Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). Cardiovascular Diabetology 21:1.
Crossref
Crossref
Jie Zhang, Tong-Zhang Xian, Yu Teng, Xiuzhi Wang, Ming-Xiao Wu, Chen Li, Weihao Wang, Fuli Man, Xianbo Zhang, Xiaoxia Wang & Li-Xin Guo. (2022) Efficacy of Exenatide Administered Twice Daily in Body Mass Index Reduction in Patients with Type 2 Diabetes Mellitus. International Journal of Clinical Practice 2022, pages 1-6.
Crossref
Crossref
Jiangchuan Long, Yongjian Liu, Yaqian Duan, Yang Li, Gangyi Yang, Ziyu Ren, Wei Tao & Dongfang Liu. (2022) Effect of GLP-1R rs2254336 and rs3765467 polymorphisms on gastrointestinal adverse reactions in type 2 diabetes patients treated with liraglutide. European Journal of Clinical Pharmacology 78:4, pages 589-596.
Crossref
Crossref
Elpiniki Rentzeperi, Stavroula Pegiou, Theocharis Koufakis, Maria Grammatiki & Kalliopi Kotsa. (2022) Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care. Journal of Personalized Medicine 12:3, pages 454.
Crossref
Crossref
Gunjan Y. Gandhi & Arshag D. Mooradian. (2021) Management of Hyperglycemia in Older Adults with Type 2 Diabetes. Drugs & Aging 39:1, pages 39-58.
Crossref
Crossref
Jianhua Ma, Bin Zhang, Jianing Hou & Yongde Peng. (2020) Efficacy and Safety of Once Weekly Dulaglutide in East Asian Patients with Type 2 Diabetes: Subgroup Analysis by Potential Influential Factors. Diabetes Therapy 12:1, pages 211-222.
Crossref
Crossref
Rona ZhouKarsten DuncanJulio LopezKjersti RichArthur Swislocki. (2020) Assessing the Continuation of Glucagon-Like Peptide-1 Receptor Agonists When Weight and HBA1C Are Not Reduced. Metabolic Syndrome and Related Disorders 18:7, pages 321-327.
Crossref
Crossref
Sanjay Kalra, Ashok Kumar Das, Rakesh Kumar Sahay, Manash Pratim Baruah, Mangesh Tiwaskar, Sambit Das, Sudip Chatterjee, Banshi Saboo, Ganapathi Bantwal, Saptarshi Bhattacharya, Gagan Priya, Manoj Chawla, Kiraninder Brar, Syed Abbas Raza, Azizul Hasan Aamir, Dina Shrestha, Noel Somasundaram, Prasad Katulanda, Faria Afsana, Shahjada Selim, Mohammad Wali Naseri, Ali Latheef & Manilka Sumanatilleke. (2019) Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force. Diabetes Therapy 10:5, pages 1645-1717.
Crossref
Crossref
Hongrong Deng, Shuo Lin, Xubin Yang, Jing Lv, Sihui Luo, Longyi Zeng, Jianping Weng & Wen Xu. (2019) Effect of baseline body mass index on glycemic control and weight change with exenatide monotherapy in Chinese drug‐naïve type 2 diabetic patients. Journal of Diabetes 11:7, pages 509-518.
Crossref
Crossref
Juan P. Frías, Elise Hardy, Azazuddin Ahmed, Peter Öhman, Serge Jabbour, Hui Wang & Cristian Guja. (2018)
Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the
DURATION
‐8 randomized controlled trial
. Diabetes, Obesity and Metabolism 20:6, pages 1520-1525.
Crossref
Crossref
M. E. Trautmann & J. Vora. (2018) Use of glucagon-like peptide-1 receptor agonists among individuals on basal insulin requiring treatment intensification. Diabetic Medicine 35:6, pages 694-706.
Crossref
Crossref
Baptist Gallwitz, Samuel Dagogo‐Jack, Vivian Thieu, Luis‐Emilio Garcia‐Perez, Imre Pavo, Maria Yu, Kenneth E. Robertson, Nan Zhang & Francesco Giorgino. (2017)
Effect of once‐weekly dulaglutide on glycated haemoglobin (
HbA1c
) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline
HbA1c
. Diabetes, Obesity and Metabolism 20:2, pages 409-418.
Crossref
Crossref
Jiaxing Tian, Fengmei Lian, Libo Yang & Xiaolin Tong. (2018) Evaluation of the Chinese herbal medicine Jinlida in type 2 diabetes patients based on stratification: Results of subgroup analysis from a 12-week trial. Journal of Diabetes 10:2, pages 112-120.
Crossref
Crossref
Weena J. Y. Chen, Michaela Diamant, Karin de Boer, Hendrik J. Harms, Lourens F. H. J. Robbers, Albert C. van Rossum, Mark H. H. Kramer, Adriaan A. Lammertsma & Paul Knaapen. (2017) Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine. Cardiovascular Diabetology 16:1.
Crossref
Crossref
Michael Horowitz, Vanita R. Aroda, Jenny Han, Elise Hardy & Chris K. Rayner. (2017) Upper and/or lower gastrointestinal adverse events with glucagon-like peptide-1 receptor agonists: Incidence and consequences. Diabetes, Obesity and Metabolism 19:5, pages 672-681.
Crossref
Crossref
Yukiko Onishi, Tomonori Oura, Akiko Matsui, Jun Matsuura & Noriyuki Iwamoto. (2017) Analysis of efficacy and safety of dulaglutide 0.75 mg stratified by sex in patients with type 2 diabetes in 2 randomized, controlled phase 3 studies in Japan. Endocrine Journal 64:5, pages 553-560.
Crossref
Crossref
Kumiko Hamano, Hiroshi Nishiyama, Akiko Matsui, Manaka Sato & Masakazu Takeuchi. (2017) Efficacy and safety analyses across 4 subgroups combining low and high age and body mass index groups in Japanese phase 3 studies of dulaglutide 0.75 mg after 26 weeks of treatment. Endocrine Journal 64:4, pages 449-456.
Crossref
Crossref
Xiaoling Cai, Wenjia Yang, Xueying Gao, Lingli Zhou, Xueyao Han & Linong Ji. (2016) Baseline Body Mass Index and the Efficacy of Hypoglycemic Treatment in Type 2 Diabetes: A Meta-Analysis. PLOS ONE 11:12, pages e0166625.
Crossref
Crossref
A Enrique Caballero. (2016) Glp-1 Analogues for the Treatment of Type 2 Diabetes in Latinos/Hispanics. Endocrine Practice 22:12, pages 1459-1461.
Crossref
Crossref
Jaime A. Davidson, Federico Perez Manghi, Maria Yu, Bruno Linetzky & Laura Fernández Landó. (2016) Efficacy and Safety of Dulaglutide in Hispanic/Latino Patients with Type 2 Diabetes in the Award Clinical Program. Endocrine Practice 22:12, pages 1406-1414.
Crossref
Crossref
Silvia Beatriz Gorban de Lapertosa, Gustavo Frechtel, Elise Hardy & Leobardo Sauque-Reyna. (2016) The effects of exenatide twice daily compared to insulin lispro added to basal insulin in Latin American patients with type 2 diabetes: A retrospective analysis of the 4B trial. Diabetes Research and Clinical Practice 122, pages 38-45.
Crossref
Crossref
Patrick M. O'Neil, W. Timothy Garvey, J. Michael Gonzalez-Campoy, Pablo Mora, Rafael Violante Ortiz, German Guerrero, Birgitte Claudius & Xavier Pi-Sunyer. (2016) Effects of Liraglutide 3.0 Mg on Weight and Risk Factors in Hispanic Versus Non-Hipanic Populations: Subgroup Analysis from Scale Randomized Trials. Endocrine Practice 22:11, pages 1277-1287.
Crossref
Crossref
B. H. R. Wolffenbuttel, L. Van Gaal, S. Durán‐Garcia & J. Han. (2016) Relationship of body mass index with efficacy of exenatide twice daily added to insulin glargine in patients with type 2 diabetes. Diabetes, Obesity and Metabolism 18:8, pages 829-833.
Crossref
Crossref
J. Ard, A. Cannon, C. E. Lewis, H. Lofton, T. Vang Skjøth, B. Stevenin & X. Pi-Sunyer. (2016) Efficacy and safety of liraglutide 3.0 mg for weight management are similar across races: subgroup analysis across the SCALE and phase II randomized trials. Diabetes, Obesity and Metabolism 18:4, pages 430-435.
Crossref
Crossref
Yukiko Onishi, Tomonori Oura, Hiroshi Nishiyama, Sumika Ohyama, Masakazu Takeuchi & Noriyuki Iwamoto. (2016) Subgroup analysis of phase 3 studies of dulaglutide in Japanese patients with type 2 diabetes. Endocrine Journal 63:3, pages 263-273.
Crossref
Crossref
M. Bounthavong, J.N. Tran, S. Golshan, N.F. Piland, C.M. Morello, A. Blickensderfer & J.H. Best. (2014) Retrospective cohort study evaluating exenatide twice daily and long-acting insulin analogs in a Veterans Health Administration population with type 2 diabetes. Diabetes & Metabolism 40:4, pages 284-291.
Crossref
Crossref
Yasuo Terauchi, Yoichi Satoi, Masakazu Takeuchi & Takeshi Imaoka. (2014) Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study. Endocrine Journal 61:10, pages 949-959.
Crossref
Crossref
Etie Moghissi. (2013) Management of Type 2 Diabetes Mellitus in Older Patients: Current and Emerging Treatment Options. Diabetes Therapy 4:2, pages 239-256.
Crossref
Crossref
Per M. Hellström. (2013) Satiety signals and obesity. Current Opinion in Gastroenterology 29:2, pages 222-227.
Crossref
Crossref
Zachary T. Bloomgarden, Lawrence Blonde, Alan J. Garber & Carol H. Wysham. (2012) Current Issues in Glp-1 Receptor Agonist Therapy for Type 2 Diabetes. Endocrine Practice 18, pages 6-26.
Crossref
Crossref